Blog
    Regulatory UpdateFor PhysiciansMay 15, 2026

    FDA peptide regulatory updates and GLP-1 safety signals

    Review FDA Category 2 listings for BPC-157 and TB-500, alongside emerging FAERS safety signals for GLP-1 receptor agonists including NAION and aspiration risks.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    1. Clinical Question

    How have recent FDA regulatory updates and post-marketing surveillance signals impacted the clinical evaluation of commonly used peptide therapies, particularly regarding compounding eligibility and safety monitoring?

    2. Evidence Snapshot

    • Regulatory Status: Multiple peptides including BPC-157, TB-500, and several growth hormone secretagogues are currently listed under FDA Category 2 for bulk substances as of March 2026.
    • Safety Signals: FAERS data contains 187,757 reports for GLP-1 receptor agonists (GLP-1 RAs) through 2023, identifying strong signals for gastrointestinal events and emerging signals for ocular and pulmonary complications.
    • Grade of Evidence: Data comprises Phase III clinical trial outcomes (STEP 1, SELECT, SURMOUNT-1), FDA warning letters, and official regulatory categorizations (503A/503B).
    • Outcomes: BPC-157, TB-500, and GHK-Cu are identified as significant safety risks or immunogenicity risks by a regulatory body, while semaglutide shows a 20% MACE reduction and significant weight loss in large-scale trials.

    3. What the Research Shows

    Regulatory Reclassifications As of March 2026, the FDA has identified several peptides as Category 2 bulk substances, rendering them ineligible for routine compounding under Section 503A. This includes BPC-157, TB-500, and GHK-Cu. The agency cites significant safety risks, immunogenicity concerns, and a lack of human safety data for these classifications. Specifically, BPC-157 was noted in warning letters issued to Tailor Made Compounding and Predator Nutrition in 2020.

    Regulatory shifts occurred for several other compounds in September 2024. Nominations for AOD-9604, CJC-1295, Ipamorelin, and Selank were withdrawn, leading to their removal from interim policy lists. Thymosin Alpha-1, although approved in over 35 countries as Zadaxin, remains a substance of concern under FDA interim policy following its removal from Category 2 pending advisory review.

    Safety Signal Surveillance Post-marketing surveillance of semaglutide via the FAERS database has identified significant adverse event patterns. Strong signals are established for nausea, vomiting, and delayed gastric emptying. These are considered expected, dose-dependent events managed through escalation. However, emerging signals have led to label updates. In 2025, pulmonary aspiration was added to the Ozempic label due to risks during general anesthesia related to delayed gastric emptying.

    Emerging ocular signals include Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases detected through December 2024, prompting a formal EMA review in January 2025. Hepatobiliary signals such as cholelithiasis and cholecystitis are noted as moderate signals, often associated with rapid weight loss.

    Clinical Trial Outcomes Phase III data for GLP-1 RAs show high efficacy. The STEP 1 trial (NCT03548935) reported a 14.9% weight loss for semaglutide, while the SURMOUNT-1 trial (NCT04184622) for tirzepatide reported 22.5% weight loss. Conversely, Thymosin Alpha-1 failed to show mortality reduction in a Phase III sepsis trial (NCT02867267).

    4. Mechanism

    • Gastrointestinal Impact: Semaglutide induces delayed gastric emptying, which can contribute to pulmonary aspiration risks during anesthesia and affect the absorption of oral medications.
    • Weight Loss and Liver Function: Rapid weight loss associated with these agents is linked to hepatobiliary events, including cholelithiasis.
    • Immunogenicity: The FDA cites immunogenicity risk as a primary concern for peptides like GHK-Cu, TB-500, and GHRP-2.
    • Cardiovascular Effects: CJC-1295 has been noted by regulators to cause increased heart rate.

    5. Limitations of the Evidence

    A primary limitation remains the lack of human exposure data for several compounded peptides like TB-500. While semaglutide has extensive Phase III data (SELECT trial reporting 20% MACE reduction), other peptides like BPC-157 and GHK-Cu lack FDA-approved drug status or standardized human safety profiles. For psychiatric signals such as suicidal ideation, current FAERS data does not support a risk higher than the background rate, although the FDA requires continued monitoring. The NAION signal is currently classified as emerging and remains under formal review by the EMA.

    6. Clinical Takeaway

    Physicians should note that BPC-157, TB-500, and GHK-Cu are currently classified by the FDA as significant safety/immunogenicity risks and are ineligible for routine compounding. For approved peptides like semaglutide, clinical focus has shifted from common GI effects to managing emerging risks, including pulmonary aspiration during surgery and ongoing evaluations of ocular health (NAION). Trial data confirms high efficacy for tirzepatide and semaglutide in weight management, while Thymosin Alpha-1 has not demonstrated mortality benefits in sepsis.

    7. Sources

    • Regulatory Records: IDs 0abdad3c, 1a160b34, 116a4f32, a11f0210, 68b0b103, c8181049.
    • FAERS Safety Signals: IDs 502f8ab5, d2135902, be753983, 60c7beaa, 4f021484, bcece5fd, afc343ed.
    • Clinical Trials: NCT03548935 (STEP 1), NCT03574597 (SELECT), NCT04184622 (SURMOUNT-1), NCT02867267 (Thymosin Alpha 1 Sepsis).

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1ghk cu

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.